MeSH tree: C04.557.386.480
About 2 meters (6.6 feet) of genetic material must fit into the nucleus of each of most of our trillions of cells, coiling and winding to form what looks like a tangled mess. But when genes are used, how they are used and ...
Aug 6, 2026
0
10
A protein that can dial down oxidative stress in cells helps some cancers resist treatment with a widely used class of drugs called BTK inhibitors, according to a study led by investigators at Weill Cornell Medicine. The ...
Aug 4, 2026
0
2
Adult childhood cancer survivors (CCS) of acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and non-Hodgkin lymphoma (NHL) frequently report mental distress, fatigue and executive function (EF) impairment, ...
Jul 30, 2026
0
6
How cancer develops and responds to treatment depends not only on the tumor cells themselves but also on the complex ecosystem of surrounding immune cells, blood vessels and connective tissue. In B-cell non-Hodgkin lymphoma, ...
Jul 28, 2026
0
4
A new Northwestern Medicine study has discovered how radiotherapy alters the immune environment within cutaneous T-cell lymphoma (CTCL) tumors, according to findings published in the Journal of the American Academy of Dermatology.
Jul 7, 2026
0
3
Researchers led by Universitätsmedizin Frankfurt and Goethe University Frankfurt have identified how particularly aggressive forms of lymphoma can be recognized. By combining genetic and proteomic analyses, the scientists ...
Jul 3, 2026
0
6
After a median follow-up of 10 years, more than one-third of patients with large B-cell lymphoma and nearly half of patients with follicular lymphoma who received a single infusion of tisagenlecleucel—the CAR T-cell therapy ...
Jun 25, 2026
0
13
UK media celebrity Jeremy Clarkson this week revealed he has been diagnosed with an aggressive form of prostate cancer.
Jun 18, 2026
0
15
Researchers at the University of Maryland School of Medicine (UMSOM) have identified a target that may improve the response to CAR T-cell therapy, a treatment for patients with recurrent or difficult-to-treat blood cancers.
Jun 15, 2026
0
4
A new study has uncovered why many patients with relapsed diffuse large B-cell lymphoma (rDLBCL) fail to respond as well as expected to newly approved cancer therapies. Patients treated with novel therapies in routine practice ...
Jun 1, 2026
0
3
